Table 6.
Relationship between length of non-steroideal anti-inflammatory drug consumption and breast cancer, according to tumor characteristics
| Variable | Category | NSAID | No consumption | Consumption ≤5y | Consumption >5y | ||
|---|---|---|---|---|---|---|---|
| Controls/cases (n) | Controls/cases (n) | OR (95 % CI) | Controls/cases (n) | OR (95 % CI) | |||
| Clinical stage | 1–2 | NSAID (all) | 1171/695 | 484/281 | 0.85 (0.69–1.06) | 255/123 | 0.69 (0.52–0.92) |
| Aspirin | 1808/1047 | 79/44 | 1.01 (0.65–1.58) | 23/8 | 0.74 (0.31–1.73) | ||
| Acetic acid derivatives | 1754/1025 | 113/53 | 0.79 (0.53–1.17) | 43/21 | 0.73 (0.38–1.42) | ||
| Propionic acid derivatives | 1351/770 | 380/234 | 0.93 (0.73–1.17) | 179/95 | 0.78 (0.57–1.08) | ||
| NSAID others | 1862/1072 | 33/24 | 1.56 (0.82–2.95) | 15/3 | - | ||
| 3–4 | NSAID (all) | 1171/136 | 484/54 | 0.85 (0.57–1.27) | 255/14 | 0.46 (0.24–0.88) | |
| Aspirin | 1808/192 | 79/11 | 1.61 (0.78–3.34) | 23/1 | - | ||
| Acetic acid derivatives | 1754/190 | 113/12 | 1.08 (0.54–2.17) | 43/2 | - | ||
| Propionic acid derivatives | 1351/147 | 380/45 | 0.91 (0.59–1.40) | 179/12 | 0.54 (0.27–1.09) | ||
| NSAID others | 1862/201 | 33/3 | - | 15/0 | - | ||
| Pathology | Ductal cancer | NSAID (all) | 1171/835 | 484/324 | 0.74 (0.60–0.91) | 255/130 | 0.60 (0.45–0.79) |
| Aspirin | 1808/1225 | 79/56 | 1.09 (0.72–1.66) | 23/8 | 0.60 (0.26–1.41) | ||
| Acetic acid derivatives | 1754/1204 | 113/64 | 0.78 (0.53–1.14) | 43/21 | 0.68 (0.36–1.30) | ||
| Propionic acid derivatives | 1351/918 | 380/270 | 0.81 (0.65–1.02) | 179/101 | 0.68 (0.49–0.94) | ||
| NSAID others | 1862/1259 | 33/28 | 1.42 (0.77–2.67) | 15/2 | |||
| Non-ductal cancer | NSAID (all) | 1171/151 | 484/50 | 0.78 (0.53–1.15) | 255/33 | 0.90 (0.55–1.48) | |
| Aspirin | 1808/228 | 79/5 | 0.59 (0.23–1.53) | 23/1 | - | ||
| Acetic acid derivatives | 1754/219 | 113/11 | 0.92 (0.45–1.87) | 43/4 | - | ||
| Propionic acid derivatives | 1351/166 | 380/40 | 0.79 (0.51–1.22) | 179/28 | 1.15 (0.67–1.96) | ||
| NSAID others | 1862/232 | 33/1 | - | 15/1 | - | ||
| Inmunohisto-chemistry | Hormone + | NSAID (all) | 1171/727 | 484/267 | 0.74 (0.60–0.92) | 256/123 | 0.69 (0.52–0.92) |
| Aspirin | 1808/1069 | 79/38 | 0.85 (0.54–1.36) | 23/10 | 0.79 (0.36–1.75) | ||
| Acetic acid derivatives | 1754/1044 | 113/50 | 0.69 (0.46–1.04) | 43/23 | 0.94 (0.51–1.75) | ||
| Propionic acid derivatives | 1351/805 | 380/221 | 0.82 (0.65–1.04) | 179/91 | 0.76 (0.55–1.05) | ||
| NSAID others | 1862/1089 | 33/25 | 1.62 (0.87–3.01) | 15/3 | - | ||
| HER2 +/Hormone- | NSAID (all) | 1171/172 | 484/61 | 0.70 (0.48–1.01) | 255/22 | 0.49 (0.28–0.87) | |
| Aspirin | 1808/244 | 79/10 | 0.89 (0.41–1.96) | 23/1 | - | ||
| Acetic acid derivatives | 1754/238 | 113/16 | 1.02 (0.29–3.60) | 43/1 | - | ||
| Propionic acid derivatives | 1351/188 | 380/47 | 0.66 (0.43–0.99) | 179/20 | 0.61 (0.33–1.12) | ||
| NSAID others | 1862/251 | 33/4 | - | 15/0 | - | ||
| Triple negative breast cancer | NSAID (all) | 1171/94 | 484/49 | 0.94 (0.60–1.48) | 255/14 | 0.60 (0.30–1.17) | |
| Aspirin | 1808/148 | 79/9 | 1.74 (0.78–3.89) | 23/0 | - | ||
| Acetic acid derivatives | 1754/144 | 113/8 | 0.85 (0.36–2.01) | 43/2 | - | ||
| Propionic acid derivatives | 1351/103 | 380/42 | 1.04 (0.64–1.68) | 179/12 | 0.68 (0.32–1.43) | ||
| NSAID others | 1862/154 | 33/2 | - | 15/1 | - | ||
OR odds ratio adjusted for age, recruitment area, education level, tobacco smoking history, BMI family history of breast cancer, number of deliveries, age at first delivery, menarche age, and menopausal status. CI: confidence interval